Sanofi’s Dupixent secures FDA priority review for CRSwNP

This article was originally published here

The priority review for Dupixent is for the treatment of adult patients whose CRSwNP is inadequately controlled. CRSwNP is a chronic disease of the upper airway. It is

The post Sanofi’s Dupixent secures FDA priority review for CRSwNP appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply